Ascendis Pharma A/S’s (ASND) “Buy” Rating Reaffirmed at Cantor Fitzgerald

Share on StockTwits

Cantor Fitzgerald reaffirmed their buy rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report released on Monday morning. They currently have a $185.00 target price on the biotechnology company’s stock.

Several other analysts have also recently weighed in on ASND. Credit Suisse Group boosted their price objective on Ascendis Pharma A/S from $80.00 to $86.00 and gave the stock an outperform rating in a report on Thursday, November 29th. ValuEngine raised Ascendis Pharma A/S from a buy rating to a strong-buy rating in a report on Wednesday, December 5th. BidaskClub upgraded Ascendis Pharma A/S from a hold rating to a buy rating in a research report on Tuesday, December 18th. Zacks Investment Research upgraded Ascendis Pharma A/S from a hold rating to a buy rating and set a $82.00 target price for the company in a research report on Friday, January 18th. Finally, Leerink Swann upgraded Ascendis Pharma A/S from a market perform rating to an outperform rating and boosted their target price for the stock from $73.00 to $90.00 in a research report on Thursday, January 24th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Ascendis Pharma A/S presently has an average rating of Buy and a consensus price target of $123.67.

Shares of NASDAQ:ASND opened at $129.13 on Monday. Ascendis Pharma A/S has a 1-year low of $53.21 and a 1-year high of $131.76.

Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Ascendis Pharma A/S by 12.7% during the 4th quarter. Geode Capital Management LLC now owns 30,743 shares of the biotechnology company’s stock worth $1,926,000 after buying an additional 3,459 shares during the period. FMR LLC grew its position in shares of Ascendis Pharma A/S by 1.2% during the 4th quarter. FMR LLC now owns 4,203,246 shares of the biotechnology company’s stock worth $263,333,000 after buying an additional 50,984 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth about $204,000. D. E. Shaw & Co. Inc. grew its position in shares of Ascendis Pharma A/S by 14.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 46,181 shares of the biotechnology company’s stock worth $2,893,000 after buying an additional 5,881 shares during the period. Finally, Partner Fund Management L.P. acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth about $1,724,000. Institutional investors own 95.41% of the company’s stock.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: Growth Stocks

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SPINDLE  Reaches Market Capitalization of $2.12 Million
SPINDLE Reaches Market Capitalization of $2.12 Million
MediBit Trading 32.3% Higher  Over Last 7 Days
MediBit Trading 32.3% Higher Over Last 7 Days
Clovis Oncology  Expected to Announce Earnings of -$1.80 Per Share
Clovis Oncology Expected to Announce Earnings of -$1.80 Per Share
BUDDY Price Down 36.7% Over Last 7 Days
BUDDY Price Down 36.7% Over Last 7 Days
Zacks: Analysts Expect Regency Centers Corp  Will Post Quarterly Sales of $274.40 Million
Zacks: Analysts Expect Regency Centers Corp Will Post Quarterly Sales of $274.40 Million
Analysts’ Weekly Ratings Updates for Pentair
Analysts’ Weekly Ratings Updates for Pentair


 
© 2006-2019 Zolmax.